nach oben

Strahlentherapie und Onkologie

Erschienen in:

09.03.2016 | Review Article

Adenosine can thwart antitumor immune responses elicited by radiotherapy

Therapeutic strategies alleviating protumor ADO activities

verfasst von: Prof. Dr. med. Peter Vaupel, M.A., Prof. Dr. rer.nat. Gabriele Multhoff

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

By studying the bioenergetic status we could show that the development of tumor hypoxia is accompanied, apart from myriad other biologically relevant effects, by a substantial accumulation of adenosine (ADO). ADO has been shown to act as a strong immunosuppressive agent in tumors by modulating the innate and adaptive immune system. In contrast to ADO, standard radiotherapy (RT) can either stimulate or abrogate antitumor immune responses. Herein, we present ADO-mediated mechanisms that may thwart antitumor immune responses elicited by RT.

Materials and methods

An overview of the generation, accumulation, and ADO-related multifaceted inhibition of immune functions, contrasted with the antitumor immune effects of RT, is provided.

Results

Upon hypoxic stress, cancer cells release ATP into the extracellular space where nucleotides are converted into ADO by hypoxia-sensitive, membrane-bound ectoenzymes (CD39/CD73). ADO actions are mediated upon binding to surface receptors, mainly A2A receptors on tumor and immune cells. Receptor activation leads to a broad spectrum of strong immunosuppressive properties facilitating tumor escape from immune control. Mechanisms include (1) impaired activity of CD4 ⁺ T and CD8 ⁺ T, NK cells and dendritic cells (DC), decreased production of immuno-stimulatory lymphokines, and (2) activation of Treg cells, expansion of MDSCs, promotion of M2 macrophages, and increased activity of major immunosuppressive cytokines. In addition, ADO can directly stimulate tumor proliferation and angiogenesis.

Conclusion

ADO mechanisms described can thwart antitumor immune responses elicited by RT. Therapeutic strategies alleviating tumor-promoting activities of ADO include respiratory hyperoxia or mild hyperthermia, inhibition of CD39/CD73 ectoenzymes or blockade of A2A receptors, and inhibition of ATP-release channels or ADO transporters.

Gaipl US, Multhoff G, Scheithauer H et al (2014) Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy. Immunotherapy 6:597–610CrossRefPubMed

Demaria S, Pilones KA, Vanpouille-Box C et al (2014) The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation. Radiat Res 182:170–181CrossRefPubMedPubMedCentral

Demaria S, Golden EB, Formenti SC (2015) Role of local radiation therapy in cancer immunotherapy. JAMA. Oncol. doi:10.1001/jamaoncol.2015.2756

Frey B, Rubner Y, Kulzer L et al (2014) Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother 63:29–36CrossRefPubMed

Zegers CM, Rekers NH, Quaden DH et al (2015) Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects. Clin Cancer Res 21:1151–1560CrossRefPubMed

Lauber K, Brix N, Ernst A et al (2015) Targeting the heat shock response in combination with radiotherapy: sensitizing cancer cells to irradiation-induced cell death and heating up their immunogenicity. Cancer Lett 368:209–229CrossRefPubMed

Ma Y, Conforti R, Aymeric L et al (2011) How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev 30:71–82CrossRefPubMed

Formenti SC, Demaria S (2013) Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 105:256–265CrossRefPubMedPubMedCentral

Georgakilas AG (2015) Role of the immune system and inflammation in ionizing radiation effects. Cancer Lett 368:154–156CrossRefPubMed

10.

Candeias S, Testard I (2015) The many interactions between the innate immune system and the response to radiation. Cancer Lett 356:173–178CrossRef

11.

Hellweg CE (2015) The Nuclear Factor κB pathway: a link to the immune system in the radiation response. Cancer Lett 368:275–289CrossRefPubMed

12.

Apetoh L, Ghiringhelli F, Tesniere A et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050–1059CrossRefPubMed

13.

Schaue D, Ratikan JA, Iwamoto KS et al (2012) Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 83:1306–1310CrossRefPubMedPubMedCentral

14.

Multhoff G, Pockley AG, Schmid TE et al (2015) The role of heat shock protein 70 (Hsp70) in radiation-induced immunomodulation. Cancer Lett 368:179–184CrossRefPubMed

15.

Twyman-Saint Victor C, Rech AJ, Maity A et al (2015) Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520:373–377CrossRefPubMed

16.

Le QT, Shirato H, Giaccia AJ et al (2015) Emerging treatment paradigms in radiation oncology. Clin Cancer Res 21:3393–3401CrossRefPubMed

17.

Persa E, Balogh A, Safrany G et al (2015) The effect of ionizing radiation on regulatory T cells in health and disease. Cancer Lett 368:252–261CrossRefPubMed

18.

Hekim N, Cetin Z, Nikitaki Z et al (2015) Radiation triggering immune response and inflammation. Cancer Lett 368:156–163CrossRefPubMed

19.

Antonioli L, Hasko G, Fornai M et al (2014) Adenosine pathway and cancer: where do we go from here? Expert Opin Ther Targets 18:973–977CrossRefPubMed

20.

Park HJ, Griffin RJ, Hui S et al (2012) Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res 177:311–327CrossRefPubMed

21.

Antonioli L, Blandizzi C, Pacher P et al (2013) Immunity, inflammation and cancer: a leading role for adenosine. Nature Rev Cancer 13:842–857CrossRef

22.

Sitkovsky MV, Kjaergaard J, Lukashev D et al (2008) Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res 14:5947–5952CrossRefPubMed

23.

Young A, Mittal D, Stagg J et al (2014) Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov 4:879–888CrossRefPubMed

24.

Spychala J (2000) Tumor-promoting functions of adenosine. Pharmacol Ther 87:161–173CrossRefPubMed

25.

Hoskin DW, Reynolds T, Blay J (1994) Adenosine as a possible inhibitor of killer T-cell activation in the microenvironment of solid tumours. Int J Cancer 59:854–855CrossRefPubMed

26.

Vaupel P, Mayer A (2016) Hypoxia-driven adenosine accumulation: a crucial microenvironmental factor promoting tumor progression. Adv Exp Med Biol 876:177–183

27.

Busse M, Vaupel P (1996) Accumulation of purine catabolites in solid tumors exposed to therapeutic hyperthermia. Experientia 52:469–473CrossRefPubMed

28.

Blay J, White TD, Hoskin DW (1997) The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 57:2602–2605PubMed

29.

Hatfield SM, Kjaergaard J, Lukashev D et al (2014) Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1alpha-dependent and extracellular adenosine-mediated tumor protection. J Mol Med 92:1283–1292CrossRefPubMedPubMedCentral

30.

Vaupel P, Mayer A (2015) Can respiratory hyperoxia mitigate adenosine-driven suppression of antitumor immunity? Ann Transl Med 3:292. doi:10.3978/j.ssn2305-5839.2015.09.23 PubMedPubMedCentral

31.

Becker JC, Andersen MH, Schrama D et al (2013) Immune-suppressive properties of the tumor microenvironment. Cancer Immmunol Immunother 62:1137–1148CrossRef

32.

Gessi S, Merighi S, Sacchetto V et al (2011) Adenosine receptors and cancer. Biochim Biophys Acta 1808:1400–1412CrossRefPubMed

33.

Di Virgilio F (2012) Purines, purinergic receptors, and cancer. Cancer Res 72:5441–5447CrossRefPubMed

34.

Muller-Haegele S, Muller L, Whiteside TL (2014) Immunoregulatory activity of adenosine and its role in human cancer progression. Expert Rev Clin Immunol 10:897–914CrossRefPubMed

35.

Fishman P, Bar-Yehuda S, Synowitz M et al (2009) Adenosine receptors and cancer. Handb Exp Pharmacol 193:399–441CrossRefPubMed

36.

Ohta A, Sitkovsky M (2001) Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414:916–920CrossRefPubMed

37.

Hatfield SM, Kjaergaard J, Lukashev D et al (2015) Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med 7:277ra30CrossRefPubMedPubMedCentral

38.

Vaupel P (1977) Hypoxia in neoplastic tissue. Microvasc Res 13:399–408CrossRefPubMed

39.

Bayer C, Shi K, Astner ST et al (2011) Acute versus chronic hypoxia: why a simplified classification is simply not enough. Int J Radiat Oncol Biol Phys 80:965–968CrossRefPubMed

40.

Vaupel P, Mayer A (2014) Hypoxia in tumors: pathogenesis-related classification, characterization of hypoxia subtypes, and associated biological and clinical implications. Adv Exp Med Biol 812:19–24CrossRefPubMed

41.

Thews O, Vaupel P (2015) Spatial oxygenation profiles in tumors during normo- and hyperbaric hyperoxia. Strahlenther Onkol 191:875–882. doi:10.1070/s00066-015-0867-6 CrossRefPubMed

42.

Stagg J, Smyth MJ (2010) Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29:5346–5358CrossRefPubMed

43.

Vaupel P (1974) Atemgaswechsel und Glucosestoffwechsel von Implantationsturmoren (DS-Carcinosarkom) in vivo. Funktionsanalyse biologischer Systeme. Steiner, Wiesbaden

44.

Mayer A, Vaupel P (2013) Hypoxia, lactate accumulation, and acidosis: siblings or accomplices driving tumor progression and resistance to therapy? Adv Exp Med Biol 789:203–209CrossRefPubMed

45.

Lardner A (2001) The effects of extracellular pH on immune function. J Leukoc Biol 69:522–530PubMed

46.

Gottfried E, Kreutz M, Mackensen A (2012) Tumor metabolism as modulator of immune response and tumor progression. Semin Cancer Biol 22:335–341CrossRefPubMed

47.

Choi SY, Collins CC, Gout PW et al (2013) Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite? J Pathol 230:350–355CrossRefPubMedPubMedCentral

48.

Mendler AN, Hu B, Prinz PU et al (2012) Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c-Jun activation. Int J Cancer 131:633–640CrossRefPubMed

49.

Adams JL, Smothers J, Srinivasan R et al (2015) Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov 14:603–622CrossRefPubMed

50.

Häusler SF, Del Barrio IM, Diessner J et al (2014) Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion. Am J Transl Res 6:129–139PubMedPubMedCentral

51.

Iannone R, Miele L, Maiolino P et al (2014) Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am J Cancer Res 4:172–181PubMedPubMedCentral

52.

Allard B, Pommey S, Smyth MJ et al (2013) Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res 19:5626–5635CrossRefPubMed

53.

Ohta A, Sitkovsky M (2014) Extracellular adenosine-mediated modulation of regulatory T cells. Front Immunol 5:304CrossRefPubMedPubMedCentral

54.

Schalper KA, Carvajal-Hausdorf D, Oyarzo MP (2014) Possible role of hemichannels in cancer. Front Physiology 5:237

55.

Vaupel P, Muller-Klieser W, Otte J et al (1984) Impact of various thermal doses on the oxygenation and blood flow in malignant tumors upon localized hyperthermia. Adv Exp Med Biol 169:621–629CrossRefPubMed

56.

Lee CT, Mace T, Repasky EA (2010) Hypoxia-driven immunosuppression: a new reason to use thermal therapy in the treatment of cancer? Int J Hypethermia 26:232–246CrossRef

57.

Ban HS, Uto Y, Nakamura l (2011) Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004-2010). Expert Opin Ther Pat 21:131–146

58.

Sitkovsky M, Ohta A (2013) Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer. J Mol Med 93:147–155

Titel: Adenosine can thwart antitumor immune responses elicited by radiotherapy
Therapeutic strategies alleviating protumor ADO activities
verfasst von: Prof. Dr. med. Peter Vaupel, M.A.
Prof. Dr. rer.nat. Gabriele Multhoff
Publikationsdatum: 09.03.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 5/2016
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-016-0948-1

Springer Medizin

Adenosine can thwart antitumor immune responses elicited by radiotherapy

Therapeutic strategies alleviating protumor ADO activities

Abstract

Background

Materials and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2016

Seed loss in prostate brachytherapy

Baseline status and dose to the penile bulb predict impotence 1 year after radiotherapy for prostate cancer

Radiation recall dermatitis induced by sorafenib

Ist beim diffus großzelligen B‑Zell-Lymphom im frühen Stadium nach der Chemotherapie eine konsolidierende Strahlentherapie erforderlich?

Professor Dr. Werner Bohndorf zum 90. Geburtstag

Verzicht auf die adjuvante Radiotherapie beim duktalen Carcinoma in situ

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie